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Histamine plays a variety of physiological
roles in the central nervous system and peripheral
tissues through the four known G protein-coupled
receptors H1, H2, H3, and H4. The histamine H3
receptor (H3R), discovered in 1983 by Arrang and
co-workers, is a presynaptic autoreceptor within the
Class A of GPCR family, which also functions as a
heteroreceptor modulating levels of others, beside
histamine, neurotransmitters such as dopamine,
acetylcholine, norepinephrine, serotonin, GABA,
and glutamate (1). This clearly justifies the great
interest H3R represents in the possible treatment of
various neurological dysfunctions and psychiatric
diseases such as schizophrenia, attention-deficit
hyperactivity disorder (ADHD), dementia, epilepsy,
obesity, narcolepsy and pain (2-6). Early genera-
tions of H3 receptor ligands were based on structures
containing the imidazole moiety, as analogs of his-
tamine, leading in many cases to the potential
drugñdrug interactions through inhibition of hepatic
cytochrome P450 enzymes as well as low oral
bioavailability or rapid metabolism and poor CNS
penetration (7). In 1998 Ganellin et al. described
active compounds with piperidine and pyrrolidine
moiety as a good replacement for the imidazole ring
(8). Now, this class of compounds is rapidly devel-
oping with unexpectedly large structural variations.
As many H3R antagonists/inverse agonists have
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zole H3 receptor antagonist. The presented study was undertaken to compare with each other the predicted
hepatic clearance values of DL76 calculated, using two most common mathematical models ìwell-stirredî and
ìparallel tubeî, based on the data obtained in in vitro experiments. The metabolic intrinsic clearance of DL76
equaled to 0.4848 mL/min/mg protein was scaled up and the values of hepatic clearance estimated from ìwell-
stirredî and ìparallel tubeî models were 55.47 mL/min/kg and 58.80 mL/min/kg, respectively. They were fur-
ther compared with pharmacokinetic parameters calculated based on the concentration-time profile obtained
following intravenous administration of DL76 to rats at the dose of 6 mg/kg. The estimated systemic serum
clearance value of 144.5 mL/h/kg and blood clearance value of 81.17 mL/min/kg indicate the potential extra-
hepatic metabolism of the investigated compound. This study demonstrates the utility of rat liver microsomes
for the prediction of DL76 hepatic clearance.
Keywords: 1-[3-(4-tert-butylphenoxy)propyl]piperidin, well-stirred model, parallel tube model, non-imidazole,
histamine H3 receptor antagonist
877
* Corresponding author: e-mail: agata.kryczyk@uj.edu.pl
878 AGATA KRYCZYK-POPRAWA et al.
failed in the first or second phase of clinical
research, further lead optimization and pharmacoki-
netic screening along with an increased understand-
ing of the role of H3Rs in human CNS diseases are
necessary as significant steps in early-stage H3R
antagonist/inverse agonist drug discovery (7).
Compound DL76 [1-[3-(4-tert-butylphenoxy)pro-
pyl] piperidine (Fig. 1) is the new promising non-
imidazole H3 receptor antagonist showing high
affinity towards the H3 receptor determined by the
assay with human H3 receptors stably expressed in
CHO-K1 cells (hKi = 22 ± 3 nM) and the ED50 equal
to 2.8 ± 0.4 mg/kg in a central histamine H3 receptor
assay in vivo after p.o. administration to mice (9). In
a rat model of vascular dementia, based on a perma-
nent bilateral occlusion of the common carotid arter-
ies (BCCAO), treatment with DL76 (6 mg/kg)
appeared to exert a considerable influence on meas-
ured memory function, especially improving work-
ing memory, rather than reference memory (10).
One of the most important processes affecting fate
of the drug in a body is elimination, and liver is con-
sidered to be the major organ of importance influ-
encing drug disposition and especially its elimina-
tion in both unchanged form and through metabo-
lites. The knowledge of processes taking place in
this organ, as well as their quantitative approach,
can be crucial to understanding the pharmacokinetic
profile of a new drug. Therefore, the lack of infor-
mation regarding DL76 metabolic profile prompted
us to conduct a preliminary pharmacokinetic study
in rats in order to provide a basis for its further
development. The biotransformation of DL76 using
rat liver microsomes was investigated for prediction
of in vitro hepatic clearance. These data were further
used to simulate in vivo hepatic clearance based on
two theoretical models of hepatic elimination:
ìwell-mixedî and ìparallel tubeî.
MATERIALS AND METHODS
Chemicals and materials 
The 1-[3-(4-tert-butylphenoxy)propyl]piper-
idine as a monobasic oxalate was supplied from the
Department of Technology and Biotechnology of
Drugs (Faculty of Pharmacy, Jagiellonian Univer-
sity Medical College, Kracow, Poland). Pentoxi-
fylline, 3,7-dimethyl-1-(5-oxohexyl)-3,7-dihydro-
1H-purine-2,6-dione (PTX), used as an internal
standard was obtained from Sigma (St. Louis, MO,
USA). HPLC grade acetonitrile, water, formic acid,
and ethyl acetate were purchased from Merck
(Darmstadt, Germany). β-nicotinamide adenine din-
ucleotide 2í-phosphate in reduced form (NADPH),
β-nicotinamide adenine dinucleotide 2í-phosphate
(NADP+), D-glucose-6-phosphate, glucose-6-phos-
phate dehydrogenase, TRIS, Folin and Ciocalteuís
phenol reagent were obtained from Sigma Aldrich
(St. Louis, MO, USA). All other chemicals and
reagents for determining microsomal protein con-
tent and conducting in vitro assay were of analytical
grade and commercially available. 
Animals
The livers used for obtaining the microsomal
fractions were collected from Male Wistar rats
(Charles River, Germany), weighing between 280
and 300 g. Rats were kept under conditions of con-
stant temperature (21-25OC) and relative humidity of
approximately 40-65% with standard light/dark
cycle and were given free access to standard rodent
food and water ad libitum. The animals did not
receive any drugs, and prior to the experiment, they
were fasted for 24 hours and then weighed. The
study was approved by the Institutional Animal Care
and Ethics Committee of the Jagiellonian University
Medical College, Krakow, Poland.
Preparation of rat liver microsomes
Rat liver microsomes were prepared using a
differential centrifugation method. Animals were
sacrificed by decapitation without anesthetics, the
livers were removed rapidly, washed immediately
with ice-cold 20 mM Tris/KCl buffer (pH 7.4),
weighed and homogenized with three volumes of
buffer. The homogenate was centrifuged at 11500 x
g for 20 min at 4OC, and the supernatant (S9 frac-
tion) was transferred to the fresh centrifuge tubes
and then centrifuged again at 100 000 g for 60 min
at 4OC. The pellets were then suspended in 0.15 M
KCl, homogenized and centrifuged at 100 000 x g
for 1 h at 4OC. The pellets from final centrifugation
were suspended in ice-cold 20 mM Tris buffer con-
taining 0.25 M sucrose (pH 7.4) and stored at -80OC
until use. All operations were carried out on the ice,
and the buffer solutions were made on the day of the
experiment and used after cooling to approx. 4OC.
Figure 1. Chemical structure of DL76
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The microsomal protein concentration was meas-
ured colorimetrically applying the Lowry method
and bovine serum albumin was used as standard
(11). The average enzyme protein concentration
determined in the microsomal suspension was 9.54
mg/mL.
Microsomal incubations
The DL76 incubation process with the biologi-
cal material was carried out in Eppendorf tubes. The
incubation medium at the volume of 0.5 mL con-
sisted of potassium phosphate buffer 0.1 mM (pH
7.4), 10 mM MgCl2, 1 mM NADPH and microsomal
protein in a final concentration of 1 mg/mL. The
incubations were initiated by the addition of 25 µL
of the substrate, generating an absolute DL76 con-
centrations of 250, 500, 1000, 2000 or 4000 ng/mL.
The mixtures were incubated at 37OC in the water
bath with slight agitation (100 rpm) and reactions
were terminated by cooling an ice and an addition of
1 mL of acetonitrile followed by vortex-mixing.
After centrifugation at 13000 g for 15 min, the upper
organic layer was pipetted out into another clean
centrifuge tube. Samples were evaporated till dry-
ness under a stream of nitrogen at 37OC, the residue
was dissolved in 100 µL of acetonitrile/water
(50/50, v/v) with IS (PTX at the concentration of 2.5
µg/mL) and used for LC/MS/MS analysis. The incu-
bation mixture without NADPH was used as the
blank control.
In order to select the appropriate incubation
medium, the tested compound was incubated with:
NADPH or NADPH generating system (1 mM
NADP, 10 mM glucose-6-phosphate, 3 U/mL glu-
cose-6 dehydrogenase phosphate). The reaction was
carried out for 5 min at a concentration of enzyme
proteins equal to 1 mg/mL. The medium containing
NADPH was chosen for further studies due to the
greater efficiency of the metabolic reaction. In order
to determine the optimal incubation time, the DL76
solution was incubated at a fixed concentration of
500 ng/mL with a microsomal fraction at the con-
centration of 1 mg/mL. Incubation was carried out
for: 2, 5, 10, 20, 30, 45 and 60 minutes. The highest
decrease in DL76 concentration was observed
between 2 and 5 min, therefore these two times were
chosen for further experiments.
In vivo study and blood serum partitioning
Male Wistar rats, 13ñ15 weeks of age and
weighing between 200 and 220 g were used for this
study. DL76 compound dissolved in 0.9% sterile
isotonic saline at a dose of 6 mg/kg was adminis-
tered intravenously. Rats were anesthetized with
thiopental at a dose of 70 mg/kg and blood samples
were collected after decapitation to centrifuge tubes
at 5, 10, 30, 60, 120 and 240 min after dosing (n =
5). Serum samples were harvested by centrifuging at
1500 g for 10 min at room temperature and stored at
-30OC until bioanalysis.
Blood to serum partitioning coefficient for
DL76 was calculated from the concentrations of
investigated drug in blood and serum. Compound
DL76 was added to blood at the ratio of 1 : 10 to
give a final concentration of 600 ng/mL. Samples
were incubated at 37OC for 2 h. Aliquots of blood
were removed at 0.5 and 2 h and the remaining
blood was centrifuged to obtain serum. Samples
were analyzed using LC-MS/MS method. 
Analytical methods
The quantitative measurements of DL76 in rat
liver microsomes were made using LC-MS/MS ana-
lytical method. LC-MS/MS system consisted of
high-performance liquid chromatograph Agilent
1100 (Agilent Technologies, Waldbronn, Germany)
and an Applied Biosystems MDS Sciex (Concord,
Ontario, Canada) API 2000 triple quadrupole mass
spectrometer equipped with an electrospray ioniza-
tion (ESI) interface. The positive ion mode was used
for ion generation and the system operated in the
selected reactions monitoring mode (SRM) monitor-
ing the transitions of the protonated molecular ions
m/z 276 to 98 for DL76 and 279 to 181 for the inter-
nal standard (PTX). Chromatographic separation
was carried out on an XBridgeôC18 (2.1 x 30 mm,
3.5 µm, Waters, Ireland) analytical column. The
mobile phase consisted of acetonitrile/water with an
addition of 0.1% of formic acid, was set at the flow
rate of 300 µl/min and the gradient elution was used.
Samples were prepared by the liquid-liquid extrac-
tion technique. A 100 µL of rat serum containing an
unknown concentration of DL76 was briefly mixed
with the 10 µL of IS (PTX at the concentration of 2.5
µL/mL) and then 1 mL of ethyl acetate was added.
The mixture was shaken on a mechanical shaker for
20 min and centrifuged at 1500 g for 15 min. The
organic layer (0.5 mL) was transferred into conical
tubes and evaporated to dryness. The dry residue
was reconstituted with 100 µL of acetonitrile/water
(50/50, v/v) mixture and an aliquot of 10 µL was
injected onto the LC-MS/MS system. The quality
control samples were prepared at different concen-
trations along the calibration range (LLOQ at 5
ng/mL, low at 40 ng/mL, medium at 400 ng/mL and
high at 1800 ng/mL of DL76). 
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In vitro calculations 
Enzymatic metabolic parameters were calcu-
lated from in vitro metabolism study with rat liver
microsomes based on the substrate disappearance
rate. KM and Vmax values were estimated by linear
regression analysis of Lineweaver-Burk plots. In
vitro intrinsic clearance was computed as Vmax/Km.
The intrinsic clearance value expressed per mil-
ligram of microsomal protein calculated from the in
vitro metabolism experiments was scaled up per
kilogram of body weight taking account of the
microsomal protein content per gram of liver ñ 61
mg/g (12) and average liver weight per kilogram of
body weight ñ 32.67 g/kg.
In vitro-In vivo scaling using the ìwell-stirredî
and ìparallel-tubeî models
The hepatic clearance was predicted from
intrinsic clearance using the equations for both the
ìwell-stirredî (Eq. 1) and ìparallel-tubeî (Eq. 2)
liver models (13):
Clint ∑ fuClH = QH ∑ EH = QH ∑ ññññññññññññ (1)QH + Clint ∑ fu
ClH = QH ∑ EH = QH ∑ (1 ñ efu ∑ Clint/QH (2)
where:
QH ñ the hepatic blood flow 
EH ñ the extraction ratio 
Clint ñ the intrinsic clearance 
fu ñ the unbound fraction of DL76 in plasma 
Pharmacokinetic analysis
Pharmacokinetic parameters were calculated
by employing a non-compartmental approach from
the average concentration values, using Phoenix
WinNonlin software (Pharsight, USA). The area
under the mean serum concentration versus time
curve extrapolated to infinity (AUC0→∞) was esti-
mated using the log/linear trapezoidal rule and the
extrapolated area calculated as Clast/λz. AUMC was
estimated by calculation of total area under the
first-moment curve by combining the trapezoid cal-
culation of AUMC0→∞ and extrapolated area deter-
mined according to the Eq. (5), where Clast is a last
measured concentration at the last sampling time
(tlast). 
tlast ∑ Clast ClastAUMC0→∞ = ñññññññññ + ññññññ  (3)λz λz2
The mean residence time (MRT) was calculated
from AUMC0→∞/AUC0→∞. The terminal rate con-
stant (λz) was calculated by log-linear regression of
the investigated compound concentration data in the
terminal phase (at least three latest sampling time
points were used) and the half-life (t1/2) was calcu-
lated as 0.693/λz. The systemic serum clearance
(ClS) was estimated from the administered dose
divided by AUC0→∞.
The blood clearance (CLB) was calculated
according to the following relationship:
CLB ∑ CB = CLS ∑ CS (4)
where CB and CS are concentrations in blood and
serum, respectively and CLS is a systemic serum
clearance. 
RESULTS
The developed LC-MS/MS method previously
described for the quantification of DL76 in rat serum
was suitable for the determination of DL76 in the
presence of its metabolite. (14). The calibration
curve for DL76 compound was generated by weight-
Figure 2. The effect of incubation time on DL76 concentration
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ed (1/x) linear regression analysis and was linear in
the range from 5 to 2000 ng/mL. The exemplary lin-
ear regression equation was y = 0.0054 x + 0.0104
for which the determination coefficient was equal to
0.9984. The limit of detection in the SRM mode was
found to be 1 ng/mL and the limit of quantification
was 5 ng/mL. The precision and accuracy for both
intra- and inter-day determination of DL76 ranged
from 2.65 to 17.03% and from 94.17 to 10.63%.
The highest decrease in DL76 concentration
was observed between 2 and 5 min, therefore these
two times were chosen for further experiments (Fig.
2). The elimination rate of DL76 was quantified at
the substrate concentrations from 250 to 4000
ng/mL to represent the enzyme kinetics. Rates of
DL76 metabolism (V0) were calculated from the
slope of the initial linear decline at each respective
substrate concentration. The plot of initial reaction
rate (ng/min/mg protein) against substrate concen-
tration (ng/mL) was hyperbolic and could be
described well by the classical Michaelis-Menten
kinetics as shown in Figure 3. Then the Lineweaver-
Burk plot was used to calculate enzyme kinetic
parameters Vmax and Km (R2 = 0.9812, P < 0.05) (Fig.
4). Pharmacokinetic parameters determined for the
biotransformation of the tested compound at sub-
strate concentrations 250-4000 ng/mL were: Vmax ñ
303.03 ng/min/mg protein, KM ñ 625 ng/mL.
The value of the intrinsic clearance for the
reaction of DL76 metabolism was 0.4848
Figure 3. Kinetic plot for the metabolism of DL76 in rat hepatic microsomes
Figure 4. Lineweaver-Burk Plot of DL76
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mL/min/mg protein which was further converted
using the physiological parameters to 981.18
mL/min/kg body weight of the rat. Subsequently,
the values of hepatic clearance were determined
based on the data obtained from in vitro experi-
ments. The two most commonly used mathematical
models describing drug elimination by the liver:
ìwell-stirrredî and ìparallel tubeî were used to pre-
dict in vivo hepatic clearance of DL76. The flow rate
value adopted at physiological level was 58.8
mL/min/kg (15). The average value of fu equal to 0.4
was assumed based on the previously published
albumin binding characteristics of DL76 compound
(16). Given the above data, the values of hepatic
clearance estimated from ìwell-stirredî and ìparal-
lel tubeî models were 55.47 mL/min/kg and 58.80
mL/min/kg, respectively.
Pharmacokinetic parameters calculated based
on the concentration-time profile after i.v. adminis-
tration of DL76 compound to rats at the dose of 6
mg/kg are presented in Table 1. Blood to serum par-
titioning coefficient equaled to 1.78 and was used to
calculate the blood clearance. The systemic serum
clearance (CLS) was 144.5 mL/min/kg and the blood
clearance (CLB) estimated according to the Eq. 6
was 81.17 mL/min/kg. 
A comparative summary of the hepatic clear-
ance values of DL76 obtained in vitro, ex vivo and in
vivo including or excluding plasma protein binding
is presented in Table 2.
The presented study was undertaken to deter-
mine the hepatic clearance of a new non-imidazole
histamine H3 receptor antagonist, compound DL76
(1-[3-(4-tert-butylphenoxy) propyl]piperidine). The
determination of intrinsic clearance for drug candi-
dates in the early discovery stage is a general prac-
tice in both academia and the pharmaceutical indus-
try (17). The application of in vitro metabolism data
using rat liver microsomes is the most common way
to predict the value of hepatic clearance in rat. The
in vitro CLint may be derived traditionally from the
metabolite formation or based on the substrate
depletion method (15, 18, 19). For the purpose of
this study, the latter approach was utilized. To
achieve appropriate estimates of in vitro kinetic
parameters it was necessary to optimize the incuba-
tion procedure of DL76 with the microsomal frac-
tion. The following conditions of the incubation
process were carefully chosen: the way of NADPH
supplementation for oxidative transformation either
by direct addition of NADPH or via an NADPH-
regenerating system, the time of incubation and the
concentration of microsomal protein. 
The quantitative relationship between intrinsic
clearance, blood flow and unbound fraction of the
investigated compound can only be understood with
the use of a conceptual model of the liver and sever-
al models and approaches have been proposed. In
the present study, the predictive ability of two math-
ematical models of hepatic clearance was verified,
Table 1. Pharmacokinetic indices of DL76 following an i.v. administration at a dose of 6 mg/kg to rats (n = 5); data are presented as me-
dian values ± SD.
Pharmacokinetic Co t0.5λz CLS AUC0→∞ Vss MRT
parameter [ng/mL] [min] [mL/min/kg] [ng∑h/mL] [L/kg] [min]
Parameter value 652.7 141 144.5 684.78 26.2 181.8
Table 2. Comparison between average values of hepatic clearance of DL76 obtained in vitro, ex vivo and in vivo.
Well-stirred model
ClintAll protein binding ignoredH ClH = QH ∑ ññññññññññññ 55.47 mL/min/kgQH + Clint
Clint ∑ fuIncluding plasma protein binding (fu) ClH = QH ∑ ññññññññññññ 51.11 mL/min/kgQH + Clint  ∑ fu
Parallel tube model
All protein binding ignored ClH = QH ∑ (1 ñ eClint/QH) 58.80 mL/min/kg
Including plasma protein binding (fu) ClH = QH ∑ (1 ñ efu∑Clint/QH) 58.73 mL/min/kg
Serum clearance 144.5 mL/min/kg
Blood clearance 81.17 mL/min/kg
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since the predictions based on these assumptions
represent the two opposite extremes of all the avail-
able models. The ìwell-stirred modelî views the
liver as a well-stirred compartment with concentra-
tion of unbound drug in the liver in equilibrium with
that in the blood, while the ìparallel tube modelî
regards the liver as a series of parallel tubes with
enzymes evenly distributed and the concentration of
unbound drug declining along the tube length (20).
Pharmacokinetic dissimilarities among this models
are mainly due to the differences in assumptions
made on the anatomical structure of the liver and the
extent of blood mixing within this organ but both of
them incorporate scaling factors affecting the hepat-
ic clearance of compounds such as protein binding,
hepatic blood flow, and enzymatic activity.
Accurate prediction of hepatic clearance requires the
appropriate use of protein binding phenomena, both
the nonspecific binding of the compound to the
microsomal milieu and binding to plasma proteins.
The inclusion of nonspecific microsomal binding is
often discussed as a potential correction factor but
currently available data also showed that its use in
the hepatic clearance calculation does not seem to
substantially improve in vitro-in vivo correlation
(18). The percentage of DL76 bound to plasma pro-
tein used for calculation in the presented manuscript
was assumed to be equal to 60% and the nonspecific
binding to microsomes was omitted (16). The afore-
mentioned data have been obtained using equilibrium
dialysis over the concentration range of 0.32 nM ñ
317.18 µM and at a physiological bovine serum albu-
min (BSA) concentration of 602 µM (16). In the pre-
sented study the hepatic blood flow rate value
assumed at physiological level was equal to 58.8
mL/min/kg, but there are large discrepancies between
the values reported in literature (from 55 to 80
mL/min/kg), which may also have an impact on the
accuracy of the in vitro/in vivo extrapolation (21, 22). 
In parallel with the in vitro assessment of the
metabolic stability, the pharmacokinetics of new
chemical entities is often examined in order to iden-
tify the major route(s) of elimination in laboratory
animals from in vitro-in vivo correlation analysis.
The systemic blood clearance of DL76 following
i.v. administration of this compound to rats was high
(81.17 mL/min/kg). This value compared with the
calculated hepatic clearance and considering the
physiological rate of hepatic blood flow in rats equal
to 58.8 mL/min/kg may indicate potential extrahep-
atic metabolism of the tested compound, which
could theoretically contribute to the discrepancies
between hepatic and systemic clearances of DL76
(23, 24, 25). Presented results may be a source of
useful information for scientists searching for new
chemical entities in this group of compounds.
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